Safety and immunologic effects of IL-15 administration in nonhuman primates.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Blood

• Publication date

  2009-09-17

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2008-12-189266PMID 19605850PMCID PMC2746471
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• primates Safety and immunologic effects of IL-15 administration in nonhuman

  2011cited by this paper
• Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines

  2008cited by this paper
• IL‐15 acts as a potent inducer of CD4+CD25hi cells expressing FOXP3

  2008cited by this paper
• Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.

  2008cited by this paper
• IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis

  2008cited by this paper
• IL-15 Treatment during Acute Simian Immunodeficiency Virus (SIV) Infection Increases Viral Set Point and Accelerates Disease Progression despite the Induction of Stronger SIV-Specific CD8+ T Cell Responses1

  2008cited by this paper
• Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells.

  2008cited by this paper
• IL-2 and IL-15 Each Mediate De Novo Induction of FOXP3 Expression in Human Tumor Antigen-specific CD8 T Cells

  2007cited by this paper
• Interleukin-15 but Not Interleukin-7 Abrogates Vaccine-Induced Decrease in Virus Level in Simian Immunodeficiency Virusmac251-Infected Macaques1

  2007cited by this paper
• The IL-15/IL-15Rα on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells

  2007cited by this paper
• cancer patients regulatory T cells in + Foxp 3 hiCD 25 + IL-2 administration increases CD 4

  2006cited by this paper
• IL-15/IL-15 receptor biology: a guided tour through an expanding universe.

  2006cited by this paper
• The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design

  2006cited by this paper
• IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.

  2006cited by this paper
• Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.

  2006cited by this paper
• Combined IL-15/IL-15Rα Immunotherapy Maximizes IL-15 Activity In Vivo1

  2006cited by this paper
• IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates.

  2006cited by this paper
• A novel autoregulatory mechanism for transcriptional activation of the IL‐15 gene by a nonsecretable isoform of IL‐15 generated by alternative splicing

  2005cited by this paper
• Expression of membrane-bound IL-15 by bone marrow fibroblast-like stromal cells in aplastic anemia.

  2005cited by this paper
• Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool.

  2005cited by this paper
• Interleukin-15 Increases Effector Memory CD8+ T Cells and NK Cells in Simian Immunodeficiency Virus-Infected Macaques

  2005cited by this paper
• IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells

  2004cited by this paper
• Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15.

  2004cited by this paper
• IL-15 is superior to IL-2 in the generation of long-lived antigen specific memory CD4 and CD8 T cells in rhesus macaques.

  2004cited by this paper
• RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma.

  2004cited by this paper
• Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity

  2003cited by this paper
• IL-15R alpha expression on CD8+ T cells is dispensable for T cell memory.

  2003cited by this paper
• IL-15Rα expression on CD8+ T cells is dispensable for T cell memory

  2003cited by this paper
• Cytokine control of memory T-cell development and survival

  2003cited by this paper
• Differential STAT3, STAT5, and NF-kappaB activation in human hematopoietic progenitors by endogenous interleukin-15: implications in the expression of functional molecules.

  2003cited by this paper
• Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines.

  2003cited by this paper
• Interleukin-15 interactions with interleukin-15 receptor complexes: characterization and species specificity.

  2002cited by this paper
• Cytokine Requirements for Acute and Basal Homeostatic Proliferation of Naive and Memory CD8+ T Cells

  2002cited by this paper
• Cutting Edge: Requirement for IL-15 in the Generation of Primary and Memory Antigen-Specific CD8 T Cells1

  2002cited by this paper
• IL-15Rα Recycles and Presents IL-15 In trans to Neighboring Cells

  2002cited by this paper
• Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

  2002cited by this paper
• Systemic Administration of IL-15 Augments the Antigen-Specific Primary CD8+ T Cell Response Following Vaccination with Peptide-Pulsed Dendritic Cells

  2002cited by this paper
• Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells

  2002cited by this paper
• Interleukin 15 Is Required for Proliferative Renewal of Virus-specific Memory CD8 T Cells

  2002cited by this paper
• IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells.

  2002cited by this paper
• Control of homeostasis of CD8+ memory T cells by opposing cytokines.

  2000cited by this paper
• A protective role of interleukin-15 in a mouse model for systemic infection with herpes simplex virus.

  2000cited by this paper
• Differential Roles of Interleukin 15 mRNA Isoforms Generated by Alternative Splicing in Immune Responses in Vivo

  2000cited by this paper
• Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.

  1999cited by this paper
• The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens.

  1999cited by this paper
• Contributions of CD4+, CD8+, and CD4+CD8+ T cells to skewing within the peripheral T cell receptor beta chain repertoire of healthy macaques.

  1999cited by this paper
• Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.

  1998cited by this paper
• The 5' untranslated region, signal peptide, and the coding sequence of the carboxyl terminus of IL-15 participate in its multifaceted translational control.

  1998cited by this paper
• Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.

  1998cited by this paper
• Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment.

  1995cited by this paper
• Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor.

  1994cited by this paper
• Utilization of the beta and gamma chains of the IL‐2 receptor by the novel cytokine IL‐15.

  1994cited by this paper
• The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.

  1994cited by this paper
• Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene.

  1993cited by this paper
• Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

  1985cited by this paper
• In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.

  1985cited by this paper
• In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

  1985cited by this paper

• Retinoids enhance NK effector function against HIV-infected CD4 T cells

  2026cites this paper
• Adoptive transfer of natural killer cells in therapeutic treatment of COVID-19 patients

  2025cites this paper
• The role of cytokines in shaping the future of Cancer immunotherapy.

  2025cites this paper
• Evaluation of clinical and immunological responses to recombinant canine interleukin-15 therapy in dogs with cancer: A pilot study.

  2025cites this paper
• IL2-independent expansion, persistence, and antitumor activity in TIL expressing regulatable membrane-bound IL15.

  2025cites this paper
• Combined CD25-targeted near infrared photoimmunotherapy (NIR-PIT) and intratumor IL-15 enhance the effectiveness of anti-PD-1 immunotherapy

  2025cites this paper
• A nanobody-based tri-specific NK cell engager targeting CD5 triggers antitumor immunity

  2025cites this paper
• Targeted LNPs deliver IL-15 superagonists mRNA for precision cancer therapy.

  2024cites this paper
• Targeted LNPs deliver mRNA encoding IL-15 superagonists to balance efficacy and toxicity in cancer therapy

  2024cites this paper
• Therapeutic approaches to enhance natural killer cell cytotoxicity

  2024cites this paper
• Immunotherapy in the Treatment of a Brain Tumor

  2024cites this paper
• Preclinical Evaluation of Off-The-Shelf PD-L1+ Human Natural Killer Cells Secreting IL15 to Treat Non-Small Cell Lung Cancer.

  2024cites this paper
• Stimulating the Antitumor Immune Response Using Immunocytokines: A Preclinical and Clinical Overview

  2024cites this paper
• Immunomodulation with IL-7 and IL-15 in HIV-1 infection

  2023cites this paper
• Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach.

  2023cites this paper
• Intratumoral interleukin-15 improves efficacy of near-infrared photoimmunotherapy.

  2023cites this paper
• Tumor eradication by hetIL-15 locoregional therapy correlates with an induced intratumoral CD103intCD11b+ dendritic cell population.

  2023cites this paper
• Improved Targeting of Therapeutics by Nanocarrier-Based Delivery in Cancer Immunotherapy and Their Future Perspectives

  2023influential citation
• Immunotherapeutic Development of a Tri-Specific NK Cell Engager Recognizing BCMA

  2023cites this paper
• Cytokine Gene Vaccine Therapy for Treatment of a Brain Tumor

  2023cites this paper
• Interleukins (Cytokines) as Biomarkers in Colorectal Cancer: Progression, Detection, and Monitoring

  2023cites this paper
• Repressing expression of difficult‐to‐express recombinant proteins during the selection process increases productivity of CHO stable pools

  2023cites this paper
• Recent advances in CD8+ T cell-based immune therapies for HIV cure

  2023cites this paper
• CAR-NK cell therapy for glioblastoma: what to do next?

  2023cites this paper
• Oncolytic therapy with recombinant vaccinia viruses targeting the interleukin-15 pathway elicits a synergistic response

  2023cites this paper
• Transient T cell expansion, activation, and proliferation in therapeutically vaccinated SIV+ macaques treated with N-803

  2022cites this paper
• Enhanced half-life and antitumor activity of Interleukin-15 through genetic fusion of a serum albumin-specific protein binder.

  2022cites this paper
• Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?

  2022cites this paper
• The pathogenetic role of some cytokines in the development and course of various clinical forms of urinary tract infections in children

  2022cites this paper
• Tracing New Landscapes in the Arena of Nanoparticle-Based Cancer Immunotherapy

  2022cites this paper
• Engineering interferons and interleukins for cancer immunotherapy.

  2022cites this paper
• Overcoming tumor resistance mechanisms in CAR-NK cell therapy

  2022cites this paper
• Biomimetic and Materials-Potentiated Cell Engineering for Cancer Immunotherapy

  2022cites this paper
• A NK Cell Odyssey: From Bench to Therapeutics Against Hematological Malignancies

  2022cites this paper
• Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia

  2022cites this paper
• 2022 update on the scientific premise and clinical trials for IL‐15 agonists as cancer immunotherapy

  2022cites this paper
• Emerging strategies for biomaterial-assisted cancer immunotherapy

  2022cites this paper
• Transient T Cell Expansion, Activation, and Proliferation in Therapeutically Vaccinated Simian Immunodeficiency Virus-Positive Macaques Treated with N-803

  2022cites this paper
• Preclinical evaluation of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15/IL15Rα complex

  2022cites this paper
• Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects

  2022cites this paper
• ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential

  2022cites this paper
• Therapeutic potential of interleukin-15 in cancer (Review)

  2021cites this paper
• NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy

  2021cites this paper
• Safety and immunological effects of recombinant canine IL-15 in dogs.

  2021cites this paper
• Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies.

  2021cites this paper
• A novel multimeric IL15/IL15Rα-Fc complex to enhance cancer immunotherapy

  2021cites this paper
• The evolution of commercial drug delivery technologies

  2021cites this paper
• Development of Stable Chimeric IL-15 for Trans-Presentation by the Antigen Presenting Cells

  2021cites this paper
• The Omentum in Obesity-Associated Cancer: A Hindrance to Effective Natural Killer Cell Migration towards Tumour Which Can Be Overcome by CX3CR1 Antagonism

  2021cites this paper
• IL-15 and IL-15Rα: Something old, something new, and something blue

  2021cites this paper
• Therapeutic Potential of IL-15 and N-803 in HIV/SIV Infection

  2021cites this paper
• A Chimeric IL-15/IL-15Rα Molecule Expressed on NFκB-Activated Dendritic Cells Supports Their Capability to Activate Natural Killer Cells

  2021cites this paper
• Protective and Therapeutic Effects of an IL-15:IL-15Rα-Secreting Cell-Based Cancer Vaccine Using a Baculovirus System

  2021cites this paper
• Nanomaterials for T-cell cancer immunotherapy

  2021cites this paper
• Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma

  2020influential citation
• Interleukin-23 engineering improves CAR T cell function in solid tumors

  2020cites this paper
• Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?

  2020cites this paper
• Rapid isolation and enrichment of mouse NK cells for experimental purposes.

  2020cites this paper
• Leveraging Immunotherapy with Nanomedicine

  2020cites this paper
• Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors

  2020cites this paper
• Interleukin-15 after Near-Infrared Photoimmunotherapy (NIR-PIT) Enhances T Cell Response against Syngeneic Mouse Tumors

  2020influential citation
• Recombinant Human Interleukin-15 and Anti-PD-L1 Combination Therapy Expands a CXCR3 + PD1 −/low CD8 T-Cell Subset in Simian Immunodeficiency Virus-Infected Rhesus Macaques

  2020cites this paper
• Targeting Prostate Cancer Using Intratumoral Cytotopically Modified Interleukin-15 Immunotherapy in a Syngeneic Murine Model

  2020cites this paper
• Cytokine and Chemokine Signals of T-Cell Exclusion in Tumors

  2020cites this paper
• To Remember or to Forget: The Role of Good and Bad Memories in Adoptive T Cell Therapy for Tumors

  2020cites this paper
• Combination rhIL-15 and anti-PD-L1 (Avelumab) enhances HIVGag-specific CD8 T cell function.

  2020cites this paper
• Recent Advances in the Use of NK Cells Against Cancer

  2020cites this paper
• IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment

  2020cites this paper
• Fueling chimeric antigen receptor T cells with cytokines.

  2020cites this paper
• The Role of Immunomodulatory Receptors in the Pathogenesis of HIV Infection: A Therapeutic Opportunity for HIV Cure?

  2020cites this paper
• Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad

  2020cites this paper
• Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15

  2019cites this paper
• Adipocytes: A Novel Target for IL-15/IL-15Rα Cancer Gene Therapy.

  2019cites this paper
• The rise of human stem cell-derived natural killer cells for cancer immunotherapy

  2019cites this paper
• Delivery technologies for cancer immunotherapy

  2019cites this paper
• IL-15 and GM-CSF stimulated macrophages enhances phagocytic activity in ENU induced leukemic mice.

  2019cites this paper
• Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?

  2019cites this paper
• rhIL-15 and anti-PD-L1 combination therapy expands a CXCR3+PD1-/low CD8 T cell subset in SIV-infected rhesus macaques.

  2019cites this paper
• The role of cytokines in the regulation of NK cells in the tumor environment.

  2019cites this paper
• NK cells to cure cancer.

  2019cites this paper
• T cell immunotherapy enhanced by designer biomaterials.

  2019cites this paper
• Cytokines in the Treatment of Cancer

  2019cites this paper
• Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy

  2019cites this paper
• Advances on Non-Genetic Cell Membrane Engineering for Biomedical Applications

  2019cites this paper
• Toward precision manufacturing of immunogene T-cell therapies.

  2018cites this paper
• Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour

  2018cites this paper
• Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis

  2018cites this paper
• Powerful anti-colon cancer effect of modified nanoparticle-mediated IL-15 immunogene therapy through activation of the host immune system

  2018influential citation
• Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy

  2018cites this paper
• 7-4-2017 New interleukin-15 superagonist ( IL-15 SA ) significantly enhances graft-versus-tumor activity

  2018cites this paper
• Treatment with native heterodimeric IL-15 increases cytotoxic lymphocytes and reduces SHIV RNA in lymph nodes

  2018cites this paper
• Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques

  2018cites this paper
• Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice

  2018cites this paper
• Cytokines in Cancer Immunotherapy.

  2018cites this paper
• Antibody-Based Cancer Therapy: Successful Agents and Novel Approaches.

  2017cites this paper
• In Vitro Culture with Interleukin-15 Leads to Expression of Activating Receptors and Recovery of Natural Killer Cell Function in Acute Myeloid Leukemia Patients

  2017cites this paper
• Antibody-cytokine fusion proteins for improving efficacy and safety of cancer therapy.

  2017cites this paper
• Characterization of Interleukin-15-Transpresenting Dendritic Cells for Clinical Use

  2017cites this paper
• Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors

  2017cites this paper
• New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity

  2017cites this paper